SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Bayer AG (BAYRY) , forward earnings yield 9.13%. PEG 0.92 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
- Forward P/E 11.0
- PEG Ratio 0.92 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
Overall SharesGrow Score: 32/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BAYRY
Valuation Multiples
P/E (TTM)0.0
Forward P/E11.0
PEG Ratio0.92
Forward PEG0.92
P/B Ratio0.00
P/S Ratio1.07
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-0.88
Forward EPS (Est.)$1.09
Book Value / Share$0.00
Revenue / Share$11.14
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Forward Earnings Yield9.13%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$1.36 |
$46.77B |
$4.53B |
9.7% |
| 2017 |
$2.07 |
$35.02B |
$7.34B |
21% |
| 2018 |
$0.45 |
$39.59B |
$1.7B |
4.3% |
| 2019 |
$0.62 |
$43.55B |
$2.43B |
5.6% |
| 2020 |
$-3.96 |
$41.4B |
$-15.56B |
-37.6% |
| 2021 |
$0.26 |
$44.08B |
$1B |
2.3% |
| 2022 |
$1.06 |
$50.74B |
$4.15B |
8.2% |
| 2023 |
$-0.75 |
$47.64B |
$-2.94B |
-6.2% |
| 2024 |
$-0.65 |
$46.61B |
$-2.55B |
-5.5% |
| 2025 |
$-0.88 |
$43.78B |
$-3.48B |
-7.9% |
